Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

Gilead’s HIV treatment meets primary trial endpoint

December 16, 2025
Research and Development Gilead, HIV/AIDS

Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a combination of bictegravir and lenacapavir …

News

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia

November 27, 2025
Product launch Gilead, HIV/AIDS

Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and Zambia, a milestone in the …

News

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024
Research and Development Gilead, HIV, Infections and infestations, clinical trial

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …

News

Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis

June 5, 2024
Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar

Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …

News

Gilead and Arcus announce results from colorectal cancer treatment trial

June 3, 2024
Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer

Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …

News

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

May 10, 2023
Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …

News
gilead-sciences

‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access

July 19, 2021
Sales and Marketing Cancer, Gilead, NHS, charity

The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge access to its new treatment …

News

Jubilant’s oral remdesivir formulation shows positive results in human trial

April 22, 2021
COVID-19, Gilead, Jubilant Pharma, covid-19 treatment, pharma, pharma news, remdesivir

Jubilant Pharma has announced the successful completion of studies in human volunteers for their oral formulation of remdesivir – an …

News
Gilead sign

Gilead’s bladder cancer drug gets FDA approval

April 15, 2021
FDA, Gilead, bladder cancer, bladder cancer treatment, pharma, pharma news

The FDA have granted accelerated approval to Gilead’s Trodelvy drug for the treatment of metastatic urothelial cancer (UC).

News
Gilead sign

FDA approve Gilead’s breast cancer treatment after Phase III trial

April 8, 2021
FDA, Gilead, Trodelvy, pharma, pharma news

The FDA has approved Gilead’s Trodelvy therapy for the treatment of metastatic triple-negative breast cancer (TNBC).

News
gilead-sciences

Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …

News
gilead-sciences

Galapagos and Gilead halt Phase III trials for idiopathic pulmonary fibrosis drug

February 11, 2021
Gilead

Galapagos and Gilead have halted the ISABELA Phase III clinical studies for their autotaxin inhibitor ziritaxestat in patients with idiopathic …

News
gilead-sciences

NICE recommends rheumatoid arthritis drug Jyseleca for NHS use

January 21, 2021
Gilead, NICE

NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …

News

European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma

December 17, 2020
Sales and Marketing CAR-T, Europe, Gilead, Kite, Tecartus

Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen receptor (CAR) T cell therapy …

News
gilead-sciences

Gilead’s lenacapavir meets primary goal in heavily treated and multidrug resistant HIV-1

November 19, 2020
Research and Development Gilead, HIV, pharma

Gilead has pulled back the curtain on promising new data for its long-acting HIV-1 capsid inhibitor lenacapavir for heavily treated …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025